Ionis Pharma up after US FDA approves rare brain disorder treatment
04/09/2026 11:00
BUZZ-Ionis Pharma up after US FDA approves rare brain disorder treatment ** Shares of Ionis Pharmaceuticals IONS.O rise 1.5% to $59 premarket
** U.S. FDA late on Thursday approved co's therapy to treat a rare disease that affects the brain
** Ionis' injectable drug zilganersen, branded Zanvastro, can be used to treat adults and pediatric patients with Alexander disease, a neurological disorder that damages brain cells and causes problems with movement, speech and swallowing
** In an early-to-late-stage study, patients who got a 50 mg dose of Zanvastro showed a statistically significant improvement in gait speed as assessed by a 10-meter walk test at 61 weeks
** Zanvastro will be available in the U.S. in the coming weeks - IONS
** As of last close, stock down 26.5% YTD
(Reporting by Siddhi Mahatole)
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study